



(12) Translation of  
European patent specification

(11) NO/EP 2849758 B1

NORWAY

(19) NO  
(51) Int Cl.  
**A61K 31/675 (2006.01)**  
**A61P 19/02 (2006.01)**  
**A61P 29/00 (2006.01)**

**Norwegian Industrial Property Office**

---

|      |                                                                      |                                                                                                                                                                                                          |                                                                                                                                                                        |
|------|----------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (21) | Translation Published                                                | 2018.06.25                                                                                                                                                                                               |                                                                                                                                                                        |
| (80) | Date of The European Patent Office Publication of the Granted Patent | 2018.04.04                                                                                                                                                                                               |                                                                                                                                                                        |
| (86) | European Application Nr.                                             | 13791356.2                                                                                                                                                                                               |                                                                                                                                                                        |
| (86) | European Filing Date                                                 | 2013.05.14                                                                                                                                                                                               |                                                                                                                                                                        |
| (87) | The European Application's Publication Date                          | 2015.03.25                                                                                                                                                                                               |                                                                                                                                                                        |
| (30) | Priority                                                             | 2012.05.14, US, 201261646538 P<br>2012.05.15, US, 201261647478 P<br>2012.06.01, US, 201261654292 P<br>2012.06.01, US, 201261654383 P<br>2012.06.05, US, 201261655527 P<br>2012.06.05, US, 201261655541 P | 2013.02.07, US, 201361762225 P<br>2013.02.14, US, 201361764563 P<br>2013.02.21, US, 201361767647 P<br>2013.02.21, US, 201361767676 P<br>2013.03.20, US, 201361803721 P |
| (84) | Designated Contracting States:                                       | AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR              |                                                                                                                                                                        |
| (73) | Proprietor                                                           | Antecip Bioventures II LLC, 630 Fifth Avenue, New York, NY 10111, US-USA                                                                                                                                 |                                                                                                                                                                        |
| (72) | Inventor                                                             | TABUTEAU, Herriot, 260 Park Avenue South Apt. 7B, New York, NY 10010, US-USA                                                                                                                             |                                                                                                                                                                        |
| (74) | Agent or Attorney                                                    | BRYN AARFLOT AS, Stortingsgata 8, 0161 OSLO, Norge                                                                                                                                                       |                                                                                                                                                                        |

---

|      |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
|------|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (54) | Title             | <b>COMPOSITIONS COMPRISING ZOLEDRONIC ACID OR RELATED COMPOUNDS FOR RELIEVING INFLAMMATORY PAIN AND RELATED CONDITIONS</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| (56) | References Cited: | WO-A1-2004/035061, JARRETT STEPHEN J ET AL: "Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis.", ARTHRITIS AND RHEUMATISM MAY 2006, vol. 54, no. 5, May 2006 (2006-05), pages 1410-1414, XP055317004, ISSN: 0004-3591, US-A1- 2007 134 319, US-A1- 2010 215 743, US-A1- 2011 098 252, US-B2- 7 704 977, Catherine McHugh, Thomas Leonard, Bozena Adamczyk, and Angela Walsh: "MER-101 tablets: A pilot bioavailability study of a novel oral formulation of zoledronic acid. (Abstract B194)", Molecular Cancer Therapeutics, vol. 6 November 2007 (2007-11), XP002750821, Retrieved from the Internet: URL: <a href="http://mct.aacrjournals.org/content/6/11_Supplement/B194.short">http://mct.aacrjournals.org/content/6/11_Supplement/B194.short</a> [retrieved on 2015-11-11], Anonymous: "Equivalent Surface Area Dosage Conversion Factors", NCIFat Frederick, April 2015 (2015-04), XP002750822, Retrieved from the Internet: URL: <a href="https://ncifrederick.cancer.gov/lasp/auc/frederick/Media/Documents/ACUC42.pdf">https://ncifrederick.cancer.gov/lasp/auc/frederick/Media/Documents/ACUC42.pdf</a> [retrieved on 2015-11-10], WO-A1-2011/014781, US-A1- 2004 087 551, CASTRO A.P.C. ET AL: "Zoledronic acid to treat complex regional pain syndrome type I in adult. Case report*", REV DOR. SATILDE, vol. 12, no. 1, January 2011 |

(2011-01), XP055176375,, CASTRO A.P.C. ET AL.: 'Zoledronic acid to treat complex regional pain syndrome type I in adult. Case report.' REV DOR. SATILDE vol. 12, no. 1, January 2011, O PAULO, pages 71 - 73, XP055176375, DATABASE PUBMED [Online] September 2004 XP055189738 & ROBINSON J.N. ET AL.: 'Efficacy of pamidronate in complex regional pain syndrome type I' PAIN MED. vol. 5, no. 3, September 2004, pages 276 - 80, DATABASE PUBMED [Online] November 2004 XP055189741 Database accession no. 15529370 & MANICOURT D.H. ET AL.: 'Role of alendronate in therapy for posttraumatic complex regional pain syndrome type I of the lower extremity' ARTHRITIS RHEUM. vol. 50, no. 11, November 2004, pages 3690 - 7, DATABASE PUBMED [Online] October 2008 XP055189746 Database accession no. 18806533 & BREUER B. ET AL.: 'An open-label pilot trial of ibandronate for complex regional pain syndrome' CLIN J PAIN. vol. 24, no. 8, October 2008, pages 685 - 9, DATABASE PUBMED [Online] 04 August 2011 XP021106089 Database accession no. 21816057 & ABE Y. ET AL.: 'Improvement of pain and regional osteoporotic changes in the foot and ankle by low-dose bisphosphonate therapy for complex regional pain syndrome type I: a case series' J MED CASE REP. vol. 5, 04 August 2011, page 349, DATABASE PUBMED [Online] April 2005 XP027666044 Database accession no. 15833263 & CHAUVINEAU V ET AL.: 'What is the place of diphosphonates in the treatment of complex regional pain syndrome I?' ANN READAPT MED PHYS. vol. 48, no. 3, April 2005, pages 150 - 7, DATABASE PUBMED [Online] 04 October 2000 XP055189751 Database accession no. 11114855 & OURA S. ET AL.: 'Bisphosphonate therapy for bone metastases from breast cancer: clinical results and a new therapeutic approach' BREAST CANCER. vol. 7, no. 4, 04 October 2000, pages 307 - 10, DATABASE PUBMED [Online] 11718191 October 2001 XP055189755 Database accession no. 11718191 & HADJIPAVLOU A.G. ET AL.: 'Paget's disease of the spine and its management' EUR SPINE J. vol. 10, no. 5, October 2001, pages 370 - 84, DATABASE PUBMED [Online] November 2003 XP055189756 Database accession no. 14623059 & EEKHOFF M.E. ET AL.: 'Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy' BONE vol. 33, no. 5, November 2003, pages 831 - 8, DATABASE PUBMED [Online] June 2003 Database accession no. 12784404 & MATSUO A. ET AL.: 'Antiinflammatory and chondroprotective effects of the aminobisphosphonate incadronate (YM175) in adjuvant induced arthritis' J RHEUMATOL. vol. 30, no. 6, June 2003, pages 1280 - 90, XP008176425, DATABASE PUBMED [Online] July 1998 Database accession no. 9679211 & GOA K.L. ET AL.: 'Risedronate' DRUGS AGING. vol. 13, no. 1, July 1998, pages 83 - 91, XP008176426, DATABASE PUBMED [Online] August 1992 XP055191286 Database accession no. 1642662 & REGINSTER J.Y. ET AL.: 'Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study' ARTHRITIS RHEUM. vol. 35, no. 8, August 1992, pages 967 - 74, XP055191191, DATABASE PUBMED [Online] October 2003 'EFFICACY OF DISODIUM-CLODRONATE IN THE MANAGEMENT OF JOINT PAIN IN RHEUMATOID ARTHRITIS. SIX MONTHS OPEN STUDY.', XP055191199 Retrieved from NCBI Database accession no. 14973430 & ROVETTA G. ET AL.: 'Efficacy of disodium-clodronate in the management of joint pain in rheumatoid arthritis. Six months open study' MINERVA MED. vol. 94, no. 5, October 2003, pages 353 - 7, XP009130385, LASLETT LAURA LOUISE ET AL.: "Zoledronic acid reduces knee pain and bone marrow lesions over 1 year: a randomised controlled trial.", ANNALS OF THE RHEUMATIC DISEASES AUG 2012, vol. 71, no. 8, August 2012 (2012-08), pages 1322-1328, XP008180591, ISSN: 1468-2060, POLASCIK THOMAS J ET AL.: "Zoledronic acid in the management of metastatic bone disease.", THERAPEUTICS AND CLINICAL RISK MANAGEMENT FEB 2008, vol. 4, no. 1, February 2008 (2008-02), pages 261-268, XP055317727, ISSN: 1176-6336, AMANAT NEGIN ET AL.: "Optimal timing of a single dose of zoledronic acid to increase strength in rat fracture repair.", JOURNAL OF BONE AND MINERAL RESEARCH : THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY FOR BONE AND MINERAL RESEARCH JUN 2007, vol. 22, no. 6, June 2007 (2007-06), pages 867-876, XP055317002, ISSN: 0884-0431, DATABASE PUBMED [Online] September 2008 XP055189761 Database accession no. 18831886 & FUJITA T. ET AL.: 'Analgesic and chondroprotective effects of risedronate in osteoarthritis assessed by electroalgometry and measurement of collagen type II fragments in urine' J INT MED RES. vol. 36, no. 5, September 2008, pages 932 - 41, WO-A2-02/43738

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

## Patentkrav

1. Zoledronsyre for anvendelse ved behandling av komplekst regionalt smertesyndrom hos et pattedyr, hvor en oral doseringsform inneholdende  
5 zoledronsyre administreres i en total månedlig dose av zoledronsyre som er omtrent 100 mg/m<sup>2</sup> til omtrent 600 mg/m<sup>2</sup> basert på pattedyrets kroppsoverflateareal.
2. Zoledronsyre for anvendelse ifølge krav 1, hvor den månedlige dosen kan gis  
10 som to eller flere individuelle doser administrert i løpet av måneden.
3. Zoledronsyre for anvendelse ifølge krav 1 eller 2, hvor pattedyret er et menneske og den totale månedlige dosen av zoledronsyre er fra 100 mg/m<sup>2</sup> til 200 mg/m<sup>2</sup>.  
15
4. Zoledronsyre for anvendelse ifølge krav 3, hvor den totale månedlige dosen administreres i 4 eller 5 ukentlige doser.
5. Zoledronsyre for anvendelse ifølge krav 3, hvor den totale månedlige dosen  
20 administreres i 28 til 31 daglige doser.
6. Zoledronsyre for anvendelse ifølge et hvilket som helst av de foregående krav, hvor pattedyret er et menneske som mottar en total ukentlig dose av zoledronsyre som er fra 10 mg til 300 mg.  
25
7. Zoledronsyre for anvendelse ifølge et hvilket som helst av de foregående krav, hvor zoledronsyren administreres som et salt av et dianion av zoledronsyre.